Pancreatic Endocrine Tumor Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Pancreatic Endocrine Tumor Market Trends and Insights

Rising Incidence of Pancreatic Neuroendocrine Neoplasms

Annual detection now approaches 6 cases per 100,000 population as cross-sectional abdominal imaging becomes routine and endocrine societies promote hormone-panel screening for high-risk groups^{[1]Society of Nuclear Medicine and Molecular Imaging, “Global PET/CT Adoption Survey,” snmmi.org}. Electronic health record alerts that flag unexplained hypoglycemia or gastrin elevation shorten referral times to imaging, which brings more patients into surgical or systemic-therapy windows when curative intent remains feasible. Greater diagnostic vigilance enlarges the treatable cohort and lengthens time on therapy, supporting steady revenue growth.

Growing Adoption of Precision Oncology Approaches

Routine Ki-67 indexing, somatostatin receptor quantification via Ga-68 DOTATATE PET/CT, and next-generation sequencing panels that identify DAXX, ATRX, and mTOR aberrations allow clinicians to match patients to PRRT, everolimus, sunitinib, or multi-kinase inhibitors with fewer trial-and-error cycles^{[2]Journal of Nuclear Medicine, “Personalized Dosimetry of 177Lu-DOTATATE,” jnm.snmjournals.org}. Dosimetry software that tailors Lu-177 activity to individual tumor burden reduces nephrotoxicity and has improved progression-free survival in prospective studies, strengthening payer confidence in high-cost radionuclide regimens.

Increasing Availability of Radionuclide Therapies

Novartis’s Lutathera validated PRRT in gastroenteropancreatic neuroendocrine tumors, and ITM-11 is poised to follow with Phase III data showing a median progression-free survival of 23.9 months versus 14.1 months with everolimus. Bristol Myers Squibb is advancing RYZ101, a 225Ac-DOTATATE alpha emitter, for Lu-177-refractory disease, creating a sequential radionuclide pathway that can extend systemic control. Investment in no-carrier-added Lu-177 and nascent Ac-225 production aims to reduce backorder risk, though short half-lives still require just-in-time logistics.

Expansion of Specialized Cancer Centers

PRRT delivery involves radiopharmacy compounding, nephro-protective amino acid infusion, and multi-disciplinary tumor boards, prompting referral consolidation into high-volume centers that consistently achieve lower complication rates. Governments in China, Japan, and South Korea are subsidizing radiopharmacy build-outs inside academic hospitals, while U.S. payers reimburse travel to designated centers of excellence, reinforcing the geographic clustering of procedures.

High Treatment Costs and Limited Reimbursement

A full four-cycle PRRT course exceeds USD 200,000 in the United States, and step-therapy policies that mandate prior failure on everolimus or sunitinib postpone access^{[3]Centers for Medicare & Medicaid Services, “National Coverage Determination for PRRT,” cms.gov}. Emerging markets lack the budget room for widespread PRRT coverage, forcing manufacturers to explore outcomes-based contracts or tiered pricing.

Diagnostic Challenges Leading to Late Detection

Small non-functional tumors evade routine CT scans, and lack of standardized high-risk screening means many patients present with metastatic disease that limits curative options. Access to Ga-68 DOTATATE PET/CT remains patchy outside academic centers, hindering early identification.

Segment Analysis

By Type of Tumor: Functional Syndromes Drive Gastrinoma Growth

Insulinoma generated the largest 34.54% share in 2025, reflecting urgent surgical demand to halt severe hypoglycemia, and it continues to anchor revenue in the pancreatic endocrine tumor market. Gastrinoma, however, enjoys the fastest 9.54% CAGR as better biochemical screening for Zollinger-Ellison syndrome and swift Ga-68 DOTATATE confirmation shortens time to targeted therapy initiation. Secondary subtypes such as VIPoma, glucagonoma, and somatostatinoma are less common but now benefit from guideline-directed hormonal workups that direct patients to high-volume centers early. The pancreatic endocrine tumor market for non-functional lesions is increasing in parallel as incidental imaging is uncovering previously missed silent tumors.

Molecular profiling is tilting therapeutic choice away from histologic classification toward receptor status and genomic context. DAXX, ATRX, and mTOR mutations guide enrollment in everolimus or cabozantinib, while high somatostatin receptor density flags suitability for PRRT. Ipsen’s move to extend Cabometyx into neuroendocrine tumors on the back of the CABINET study shows how multi-kinase inhibition can capture tumors with low SSTR expression. Over time, tumor-type segmentation may blur as clinicians prioritize molecular markers over hormone secretion patterns.

Note: Segment shares of all individual segments available upon report purchase

By Treatment Type: Chemotherapy Gains Momentum in Metastatic Disease

Surgical resection provided 42.43% of 2025 revenue, buoyed by minimally invasive approaches that trim length of stay and postoperative morbidity. Yet systemic chemotherapy is climbing at a 9.87% rate because metastatic incidence is rising and temozolomide-based doublets deliver higher objective response in grade 2–3 tumors. PRRT straddles both targeted therapy and radiation domains, blurring lines as it delivers beta or alpha particles only to SSTR-positive cells.

Combination sequencing dominates decision trees. Clinicians often move from long-acting somatostatin analogs to chemotherapy, then to Lu-177 PRRT, and reserve alpha emitters such as RYZ101 for Lu-177-refractory disease. The pancreatic endocrine tumor market share commanded by radiation therapy will expand once alpha platforms clear Phase III hurdles, as dose-limited kidneys benefit from the shorter path length of alpha particles.

By Diagnosis Type: Blood Tests Emerge as Liquid Biopsy Gains Traction

Imaging still leads with 44.56% share because Ga-68 DOTATATE PET/CT detects sub-centimeter SSTR-positive lesions and informs surgical mapping. Endoscopic ultrasound-guided biopsy remains essential for Ki-67 grading. However, blood tests are on pace for a 10.11% CAGR as chromogranin A, pancreatic polypeptide, and next-generation liquid biopsies move from research into routine surveillance programs.

Combining Ga-68 DOTATATE with FDG PET/CT distinguishes indolent from aggressive disease, guiding the selection of the first-line modality. High FDG uptake with weak SSTR expression suggests a chemotherapy-rich path, whereas the opposite profile points to PRRT. As serial circulating tumor DNA assays mature, they will shrink reliance on repeat imaging, lowering lifetime diagnostic cost and driving earlier therapeutic switches.

Note: Segment shares of all individual segments available upon report purchase

By End-User: Specialized Clinics Capture Complex Cases

Hospitals retain the majority, 52.45% volume, because surgery and acute hormone crisis management drive inpatient demand. Yet specialized oncology and endocrine clinics are clocking a 10.32% CAGR as outpatient PRRT suites open inside academic networks. Ambulatory surgical centers are performing laparoscopic enucleations, while telehealth follow-up extends care to rural areas without compromising protocol adherence.

Payers increasingly route complex cases to centers of excellence that maintain integrated radiopharmacy, nuclear medicine, endocrinology, and surgery teams under one roof. This model improves renal safety monitoring and days-to-next-cycle scheduling, supporting superior real-world outcomes that justify bundled-payment contracts.

Geography Analysis

North America accounted for 43.11% of revenue in 2025, driven by dense academic networks, early Ga-68 DOTATATE adoption, and Medicare reimbursement for PRRT. FDA acceptance of ITM-11’s NDA indicates an imminent product launch, which could temper prices but raise procedural costs. Canada reimburses Lutathera province-by-province, while Mexico’s private sector drives radionuclide volume yet still faces isotope shortages.

Europe operates under unified ENETS guidelines and benefits from robust isotope logistics via central reactors in Germany, the Netherlands, and Belgium. Germany and France have the highest treatment volumes, while Italy relies on cross-border referrals from Eastern Europe. European priority review accelerates orphan therapy launches, helping sustain the size of the pancreatic endocrine tumor market across the bloc.

Asia-Pacific posts the fastest 8.54% CAGR through 2031 as China’s National Medical Products Administration greenlights ITM-11 Phase III trials and provincial governments bankroll nuclear-medicine suites. Japan reimburses Lutathera under national health insurance and is expanding alpha-therapy clinical programs. India, Australia, and South Korea are growing from smaller bases, driven by private oncology chains and academic collaborations, but they still wrestle with supply chain lags and uneven payer coverage.